"Acadia will not want to pursue New Indications with Trofinetide and instead want to participate in the New Indications by using NNZ-2591"
The agreement says that new indications are only those where Acadia is seeking to develop Trofinetide for a condition. It has nothing to do with Neuren developing NNZ 2591 for anything other than Rett and Fragile X.
The notion that each time Neuren tries to do something with NNZ2591, Acadia will pop up and insist that it is developing the same thing with Trofinetide is absurd. You guys really need to get out of your Hot Copper bubble and get a smell of the real world.
"Acadia will not want to pursue New Indications with Trofinetide...
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.626B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |